Mandate

Vinge has advised Autoliv and Veoneer

Vinge has advised Autoliv, Inc. (“Autoliv”) and Veoneer, Inc. (“Veoneer”) in connection with the spin-off and listing of Veoneer on the New York Stock Exchange and Nasdaq Stockholm. First day of regular trading of Veoneer was July 2, 2018.

On December 12, 2017, Autoliv announced that, following the conclusion of a strategic review by the board of directors, it intended to spin-off its Electronics business segment, creating a new, independent publicly traded company called Veoneer, Inc. To implement the spin-off, Autoliv has transferred the Electronics business to Veoneer and its subsidiaries and has distributed 100% of the outstanding shares of common stock of Veoneer on a pro rata basis to existing holders of common shares of Autoliv, including shares represented by Swedish Depository Receipts (“SDRs”). In connection with the spin-off and the listing of shares of Veoneer common stock on the New York Stock Exchange and Veoneer SDRs on Nasdaq Stockholm, Autoliv and Veoneer have prepared a registration statement as well as a Swedish prospectus. The registration statement became effective and the prospectus was approved and registered on June 8, and the first day of regular way trading of Veoneer was July 2, 2018.

Veoneer is a growing technology company, focused on active safety, ADAS, autonomous driving and automotive safety electronics. Veoneer’s purpose is to create trust in mobility.  In 2017, Veoneer (as the Electronics business segment of Autoliv) had a turnover of $2.3 billion. Veoneer currently has around 7,600 associates out of which roughly half are in RD&E. Veoneer’s customers are nearly all the top automotive manufacturers in the world. The market value of Veoneer, Inc. on the first day of trading was approximately SEK 34 billion.

Vinge’s team primarily consisted of Göran Nyström, Dain Hård Nevonen, Malte Hedlund, Sabina Kihlberg and Stephanie Stiernstedt, as well as Albert Wållgren, Helena Håkansson, Lionardo Ojeda and Sara Osman regarding financing issues.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025